The Pharma Data

MAY 18, 2021

This business developed positively in the Europe/Middle East/Africa region and in Latin America, partly as a result of higher prices, whereas it shrank in North America, in part due to a license expiration. This was mainly due to expanded volumes in China and Russia, while business in Germany declined substantially.

Sales 40

Sales Production Marketing Containment 40

The Pharma Data

NOVEMBER 5, 2020

Collegium will grant Teva a license to market its generic version of Xtampza ER in the United States beginning on or after September 2, 2033 (subject to U.S. This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Research and development. . 144,572. .

Production 52

Production Marketing Sales Manufacturing 52

The Pharma Data

NOVEMBER 5, 2020

Business Highlights. Key Pipeline Progress Regeneron has more than 20 product candidates in clinical development, including five marketed products for which it is investigating additional indications. Corporate and Business Development Update. Research and development (R&D). $. Oncology Program. government.

Sales 52

Sales Production Manufacturing Antibody 52

XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. They are committed to capitalizing on growth opportunities primarily through the advancement of their own product pipeline and constantly improving their existing products, as well as through business development activities. Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

AUGUST 6, 2020

Research and development expenses increased 90% to $2.5 announced that the companies submitted the Biologics License Application (BLA) to the U.S. Research and development expense. Marketing, selling and administrative expenses increased 51% to $1.6 billion in the quarter primarily due to $1.1 Regulatory. Approximately 74%.

Production 52

Production Branding Marketing Licensing 52

The Pharma Data

DECEMBER 17, 2020

George Yeh, President of TLC, commenced the conference and welcomed the company’s new Chief Business Officer, Mr. Tom Bliss. With experiences attained in licensing and business development functions from Amgen, Baxter and Johnson & Johnson, Mr. Bliss introduced himself in Mandarin Chinese. SOUTH SAN FRANCISCO, Calif.

Clinical Trials 40

Clinical Trials Clinical Trials Trials Containment 40

The Pharma Data

NOVEMBER 15, 2020

Prior to Celgene, she held leadership roles in marketing, sales and new business development from 2002 to 2011 at Johnson & Johnson. Shah previously served as Chief Executive Officer and a member of the board of directors of BioMotiv, an accelerator company aligned with the Harrington Project for Discovery & Development, a U.S.

Clinical Trials 40

Clinical Trials Clinical Trials Production Trials 40

The Pharma Data

MAY 4, 2021

to $3.65, Primarily Reflecting Updates to Anticipated Contributions from BNT162b2 Partially Offset by Additional R&D Expenses for Vaccines to Protect Against COVID-19 as Well as Other mRNA-Based Development Programs and COVID-19 Antivirals. Raises Full-Year 2021 Guidance (3) for Revenues to a Range of $70.5 previously $59.4

Vaccination 40

Vaccination Vaccine Production Sales 40

The Pharma Data

DECEMBER 23, 2020

Agreement leverages Aurobindo’s existing development, commercial and manufacturing infrastructure. Commenting on the development, Mr. N. This vaccine has immense potential in eliminating shedding, and hence containing, the spread of the pandemic.” . HYDERABAD, India , Dec.

Vaccination 52

Vaccination Vaccine Development Manufacturing 52

Pharmaceutical Technology

FEBRUARY 16, 2023

The document contains detailed information on the suppliers and their product offerings, alongside contact details to aid your purchasing or hiring decision.

Engineer 130

Engineer Manufacturing Containment Production 130